BOTHELL, Wash. / Nov 13, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. “Immunome continues to advance its pipeline,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer.... Read More

BOTHELL, Wash. / Nov 05, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13 th at 10:30am Eastern Time. Interested parties can... Read More

BOTHELL, Wash. / Nov 01, 2024 / Business Wire / Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800... Read More

IM-1021 showed superior potency when compared to a competitor in both mantle cell lymphoma and triple-negative breast cancer preclinical models; IND submission expected in 1Q25 HC74, Immunome’s proprietary TOP1 ADC payload, shows superior potency, desirable ADME properties, and enhanced efficacy in chemo-resistant cell lines when compared to deruxtecan BOTHELL, Wash. / Oct 29, 2024 / Business Wire / Immunome, Inc. (Nasdaq:... Read More

BOTHELL, Wash. / Oct 18, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on... Read More

BOTHELL, Wash. / Oct 08, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at... Read More

BOTHELL, Wash. / Oct 08, 2024 / Business Wire / Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 3, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 851,400... Read More

BOTHELL, Wash. / Sep 13, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress, being held in Barcelona from... Read More

BOTHELL, Wash. / Aug 29, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested... Read More

BOTHELL, Wash. / Aug 12, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. “Immunome is focused on establishing and developing a broad pipeline of differentiated oncology therapies. We continue to... Read More

BOTHELL, Wash. / Jul 25, 2024 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on recent business development activity, including three recently closed transactions that are expected to enhance the company’s antibody-drug conjugate (ADC) capabilities. Immunome acquired worldwide, exclusive... Read More

BOTHELL, Wash. / Jun 27, 2024 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug... Read More

BOTHELL, Wash. / May 20, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical... Read More

BOTHELL, Wash. / May 17, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since... Read More

Integration of AL102 and IM-1021 completed Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 IM-1021 and IM-3050 IND submissions expected in first quarter of 2025 BOTHELL, Wash. / May 14, 2024 / Business Wire / Immunome, Inc . (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first... Read More

BOTHELL, Wash. / May 08, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time. Interested parties can access the live audio... Read More

BOTHELL, Wash. / May 02, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy. “Immunome is... Read More

BOTHELL, Wash. / Apr 25, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards. “Immunome is pleased to... Read More

BOTHELL, Wash. / Apr 05, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present... Read More

Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 BOTHELL, Wash. / Mar 28, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the... Read More

BOTHELL, Wash. / Mar 26, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. “AL102 is a high-quality asset that complements our existing pipeline of targeted cancer therapies,” said Clay... Read More

BOTHELL, Wash. / Mar 07, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 4:20 p.m. ET. Interested parties can access the live audio webcast for... Read More

BOTHELL, Wash. / Mar 01, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET. Interested parties can access... Read More

Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month BOTHELL, Wash. / Feb 20, 2024 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient... Read More

BOTHELL, Wash. / Feb 16, 2024 / Business Wire / Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price... Read More

BOTHELL, Wash. / Feb 13, 2024 / Business Wire / Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome... Read More

BOTHELL, Wash. / Feb 13, 2024 / Business Wire / Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its common stock. All of the shares are being offered by Immunome. In... Read More

BOTHELL, Wash. / Feb 05, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome management will present at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday, February 8 at 9:30 a.m. ET. Interested parties can access the live audio webcast for this... Read More

Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties BOTHELL, Wash. & SAN DIEGO & NEW YORK / Jan 08,... Read More

BOTHELL, Wash. / Jan 04, 2024 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products. “Immunome is... Read More

BOTHELL, Wash. / Jan 03, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT. Interested parties can access the live audio webcast for this... Read More

BOTHELL, Wash. & EXTON, Pa. / Jan 02, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets and has served as a corporate director for multiple... Read More

SEATTLE & EXTON, Pa. / Dec 26, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets and materials. “We believe that novel and underexplored targets will drive the... Read More

SEATTLE & EXTON, Pa. / Nov 10, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET. Interested parties can access the live audio webcast for this... Read More

Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO Bob Lechleider, M.D., appointed as Chief Medical Officer Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors Cash runway expected to extend into Q1 2026* SEATTLE &... Read More

Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors SEATTLE & EXTON, Pa. / Nov 08, 2023 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors. Mr. Bienaimé... Read More

Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies SEATTLE & EXTON, Pa. / Oct 19, 2023 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical... Read More

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026* Expected to submit three investigational new drug applications (INDs) within 18 months SEATTLE & EXTON, Pa. / Oct 03, 2023 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a... Read More

EXTON, Pa. / Aug 09, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We believe combining Immunome and Morphimmune’s technologies represents a major... Read More

The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall , Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125 million private placement investment with leading... Read More

EXTON, Pa. / May 23, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “ IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of... Read More

EXTON, Pa. / May 05, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The external validation of our Discovery Engine through our collaboration with... Read More

EXTON, Pa. / Mar 09, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13 th Annual World ADC London conference, taking place from March 13-16, 2023. World ADC London is Europe’s longest... Read More